Kornimate/medical-research-clean huggingface dataset:
alcohol and sexual risk behavior

Conditions: Sexually Aggressive Behavior; Risky Sexual Behavior; Heavy Episodic Drinking

Summary: the current study proposes to develop, refine, and conduct a preliminary randomized controlled trial (rct) of an innovative prevention program that is the first to (a) simultaneously target heavy episodic drinking (hed), sexually aggressive behavior (sab), and risky sexual behavior (rsb) among college men; (b) integrate personalized feedback and cognitive training strategies; and (c) target the five major modifiable risk factors for sab: hed, impersonal sex, misperceptions of sexual interest, rape-supportive attitudes, and peer influence. the program will be computer-delivered as this approach is well received by college students.

the study will include three phases (pilot feasibility n=10; pilot acceptability/efficacy n=40; rct n=140), with 190 men at risk for hed, rsb, and sab. participants in the rct will be randomly assigned to either the computer-based program or services as usual at 2 large public universities in the midwest and southwest u.s. the three study phases will address the following aims: aim one: examine the feasibility of the computer administered personalized feedback and cognitive training approach (phase i; n=10), and the acceptability and efficacy of individual intervention components based on skills assessments and interviews at 1-month follow-up (phase ii; n=40). data from phases i and ii will be used to modify and streamline the intervention prior to the rct (phase iii). aim two: in an rct (n=140), evaluate whether the prevention program impacts cognitive training and personalized feedback targets at 1-month follow-up, relative to services as usual (sau). cognitive training targets include (a) enhanced focus on women's affect; (b) reduced focus on women's non-affective cues; and (c) correction of over-perceptions of women's sexual interest. personalized feedback targets include (a) increased readiness to change; (b) increased perceptions of risk; and (c) reduced misperceptions of peer attitudes and behaviors. aim three: evaluate whether the prevention program shows short-term effects on attitudinal (e.g., rape supportive and sociosexual attitudes) and behavioral outcomes (sab, hed, and rsb) at 1-month follow-up.

Eligibility criteria:
inclusion criteria: * 1) be male college students aged 18-19 at asu or iowa; * 2) report at least one binge-drinking episode in the last month; * 3) be unmarried and not engaged to be married; * 4) be heterosexual or bisexual; * 5) be dating or sexually active with women; and * 6) be above the mean in rape supportive attitudes relative to 3000 college males in prior studies conducted at the two sites. exclusion criteria: * do not meet the inclusion criteria

Keywords: personalized feedback cognitive skills training sexually aggressive behavior risky sexual behavior heavy episodic drinking
safety of short-course of nsaids in pediatric patients with ckd

Conditions: Chronic Kidney Disease; Pediatric Urology

Summary: the purpose of this study is to determine if non-steroidal anti-inflammatory (nsaid) use in the postoperative setting increases the risk of acute kidney injury (aki) in pediatric patients with mild-to-moderate chronic kidney disease (ckd). the investigators hypothesize that there is no increased risk. this will be a limited pilot study within a pediatric urology population, intended to inform future work in a larger patient population.


Eligibility criteria:
inclusion criteria: * patients over 18 months of age * diagnosis of ckd stages 2-3a, confirmed by cystatin c laboratory testing within 6 months of surgery exclusion criteria: * diagnosis of ckd stage 1 or 4-5 * home medications of angiotensin converting enzyme inhibitors (acei, such as lisinopril or captopril) or angiotensin receptor blocker (arb, such as losartan, valsartan) diuretics, or trimethoprim * iv contrast in last 30 days * pmh of renal transplant, diabetes, hypertension, nephrotic syndrome or heart failure, asthma, or hyperthyroidism * history of hyperkalemia * recent glucocorticoid exposure * procedure for oncologic indications * ongoing viral or fungal infection, or chemotherapy * allergy to nsaids

Keywords: nsaids ckd pediatrics urology post-surgical
cumulative irritation patch test

Conditions: Allergy; Irritation; Sensitization

Summary: a cumulative patch test with a challenge phase is a test devised to ascertain if a chemical agent or agents have the potential to cause contact irritation or contact allergy in the skin. allergy is only elicited in immunologically competent individuals who have become sensitized through exposure to the chemical agent at a sufficient concentration and for a sufficient duration of time.


Eligibility criteria:
inclusion criteria: * subjects must not have any visible skin disease that might be confused with a skin reaction to the test trial; * subjects must not be participating in another clinical trial at this facility or any other facility; * subjects must be willing to avoid using topical or systemic steroids or antihistamines for at least 7 days prior to trial initiation and during the duration of the trial; * subjects must understand and execute and informed consent form; * subjects must be capable of understanding and following directions; * subjects must be considered reliable; * subjects must be aged 16 to 79 years, inclusive; * subjects aged less than 18 years must have a parent or legal guardian execute the informed consent form. exclusion criteria: * subjects in ill health or taking medications, other than birth control, which could influence the purpose, integrity or outcome of the trial; * female subjects who report orally they are pregnant, planning to become pregnant or nursing during the course of the trial; * subjects who have a history of adverse reactions to adhesive tape, cosmetics, over-the-counter drugs or other personal care products; * subjects judged by the pi to be inappropriate for the trial.
three combinations of docetaxel and irinotecan for recurrent or metastatic non small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: a multicenter randomized phase ii study evaluating the activity and tolerability of three different combinations of docetaxel (taxotere) and irinotecan (campto) as second line therapy for recurrent or metastatic non small cell lung cancer (nsclc)


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven nsclc * recurrent or metastatic ncslc exclusion criteria: * prior malignancies; except for cured non melanoma skin cancer, curatively treated in situ carcinoma of the cervix or other cancer adequately treated an with non evidence of disease for at least 5 years * history or presence of brain or meningeal metastases
study of endothelial keratoplasty outcomes

Conditions: Fuchs' Endothelial Corneal Dystrophy; Bullous Keratopathy; Iridocorneal Endothelial Syndrome; Posterior Polymorphous Dystrophy

Summary: endothelial keratoplasty is a cornea-sparing transplant technique that replaces only the diseased endothelial cell layer of the patient's cornea. this technique offers many advantages compared with traditional full-thickness cornea transplants. patients experience minimal change in glasses prescription and usually recover useful vision within weeks. visual fluctuations are minimal during the healing process. the patient's cornea remains structurally intact and is more resistant to injury. endothelial keratoplasty is undergoing rapid and widespread adoption. between 2005 and 2007, the number of corneas placed by us eye banks for endothelial keratoplasty increased ten-fold (2007 eye bank association of america annual report). however, the procedure is less than 10 years old, and little is known about long term outcomes. endothelial keratoplasty candidates at our center are invited to participate in an open enrollment, prospective study of the long-term outcomes of this procedure.


Eligibility criteria:
inclusion criteria: * male or female aged 18 or older * scheduled to undergo endothelial keratoplasty * able to provide written informed consent. exclusion criteria: * age less than 18 years

Keywords: failed penetrating keratoplasty
engage for late-life depression and comorbid executive dysfunction

Conditions: Depression in Old Age; Psychotherapy; Mild Cognitive Impairment; Executive Dysfunction

Summary: although there are an increasing number of mental health treatment adaptations for older adults, there are still a number of factors to consider when making these adaptations. cognitive decline is one such factor that places significant burden on older adults and can interfere with traditional mental health therapies. engage is a behavioral treatment approach that has shown to be effective in treating late life depression. the investigators are testing the feasibility of engage as a treatment method for late life depression in older adults with cognitive decline. the objective is to corroborate engage as an alternative late life depression treatment method for a sub-population of older adults with cognitive decline. cognitive decline poses a unique mental health treatment barrier that is often over looked in younger populations. with a relatively higher prevalence of cognitive decline in older adulthood, it is imperative that a feasible mental health treatment program that can be effective in the presence of cognitive decline.


Eligibility criteria:
inclusion criteria: * age 60 or older * ability to read, write, and speak english * located in las vegas or surrounding area * ability to travel to unlv campus by self or possible caregiver for regular study visits * clinically significant symptoms of depression as evidenced by: 1) scores \> 5 on the geriatric depression scale-short form (gds-sf) * mild cognitive impairment as evidenced by: 1) scores \> 18 and \< 25 on the montreal cognitive assessment (moca) exclusion criteria: * active suicidal ideation * history of suicide attempt(s) * current symptoms of: 1) psychosis; 2) active substance use disorder * reported history of: 1) bipolar disorder ("manic depression"); 2) intellectual disability * currently in or scheduled to initiate individual psychotherapy to avoid treatment interference * psychotropic medication permitted if dose was stable over the past 2 weeks * currently living in an institutional setting (e.g., assisted living, inpatient, skilled nursing) * presence of notable memory-specific cognitive deficits as evidenced by: scores \< 9 on the moca memory subscale (rendering it difficult to participate in and track/recall events for weekly psychotherapy)

Keywords: older adults late-life depression
discontinuing disease-modifying therapies in stable relapsing - onset multiple sclerosis (dot-ms).

Conditions: Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis, Secondary Progressive

Summary: the aim of this study is to identify whether it is possible to safely discontinue treatment in relapsing-onset ms patients who have shown no evidence of active inflammation in the years prior to inclusion clinically and/or radiologically. the secondary objectives address the questions whether the discontinuation of first-line treatment has an effect on disability progression and whether the discontinuation of first-line treatment improves the quality of life for the patient. furthermore, blood collections will be included to assess whether it is possible to retrospectively predict possible return of inflammatory activity with biomarkers such as neurofilament light (nfl) or patient characteristics such as disease activity prior to disease modifying therapy (dmt). in case of emerging disease activity after the cessation of therapy we will assess if reinitiation will lead to neda again, and if there are long-term consequences. if possible, post-hoc analysis are performed for the different types of treatment compounds.


Eligibility criteria:
inclusion criteria: * minimum age of 18 years * ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (phi) in accordance with national and local privacy regulations. * definite diagnosis of relapsing-onset ms according to the revised mcdonald 2017 criteria * treatment with one of the first-line dmts: any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide * complete absence of inflammatory activity (no objectively defined and confirmed relapses, no significant number (2 or more) of new-t2 lesions and no contrast-enhancing lesions) for 5 consecutive years under first-line treatment exclusion criteria: * a switch between first-line disease modifying therapy over two years prior to inclusion, in case the switch has been due to in effectivity of the first dmt. * women who want to discontinue medication because of a pregnancy wish and women who are pregnant or expect to become pregnant during the study period * patients that have previously used interferon-beta and have been tested positive for neutralizing antibodies (nabs).

Keywords: multiple sclerosis disease modifying therapy
hematology biobank : invitro study of blood disorders

Conditions: Hematological Disorders

Summary: this is a bio repository of blood specimens from subjects with different hematological disorders.

there has been a marked increase in our knowledge of blood disorders in the last decade. much of this knowledge comes from examining blood specimens from patients and subjecting these samples to red cell, plasma, serum or dna analyses. we propose to set up a hematology biobank, which will include patient histories, their medical progress and a linked but de-identified bank of blood samples. this will enable us to have a large database, which can be used to learn more about these diseases. the hematology biobank will use whole blood, red blood cells, plasma, serum and/or dna.

Eligibility criteria:
inclusion criteria: above 18 years of age and able to consent exclusion criteria: none

Keywords: hematology biobank
attachment and biobehavioral catch-up and depression treatment

Conditions: Maternal Depression; Child Behavior Problem

Summary: maternal depression influences the development of children's behavior problems and vice versa; however most interventions singularly address maternal depression or children's behavior problems rather than both. this project assesses the efficacy of an intervention that treats both mothers and children in an integrated manner. effects are expected to disrupt the reciprocal relations that perpetuate maternal and child mental health problems over time.

the proposed project is a pilot randomized controlled trial to evaluate the effectiveness of an integrated intervention that dually treats maternal depressive symptoms and offspring behavior problems. families (n = 40 mothers and their 2-to-4 year-old children) will be randomized to receive 10 sessions of abc or 10 sessions of abc+d in their home. abc+d is an expanded version of abc that additionally treats maternal depressive symptoms using mothers and babies adapted for mothers of toddlers. the specific aims of this proposed project are: aim 1. collect preliminary data on the feasibility and acceptability of abc+d in preparation for a small pilot randomized controlled trial (rct). aim 2. conduct a small pilot rct to examine the effectiveness of abc and abc+d aim 3: assess the overall acceptability (mother- and provider-rated), appropriateness (mother- and provider-rated), and feasibility (provider-rated) of abc+d. mothers will also rate their satisfaction with each session and the degree to which it was helpful, interesting, and comprehensible.

Eligibility criteria:
inclusion criteria: 1. mothers 18 years of age or older with heightened depressive symptoms as determined by a score of 5 or higher on the patient health questionnaire-9 (phq-9) 2. biological children (of mothers described above) between 2 and 4 years old with heightened behavior problems as determined by a score of at least 3 in at least 1 domain of functioning on the impairment rating scales 3. english- or spanish-speaking exclusion criteria: 1. self-reported history of psychosis or active suicidality as defined by self-report of a specific suicide plan or recent attempt 2. child diagnosis of autism
usage test on a new cosmetic product: mouthwash

Conditions: Sensitive Gum; Gum Inflammation

Summary: the goal of this clinical trial is to learn if a new mouthwash can help soothing oral mucosa in adult patients with sensitive gums. the main questions it aims to answer are: * does the investigated mouthwash soothe red gum? * has the mouthwash antibacterial activities? researchers will compare with a marketed mouthwash to see if the observed effect is due to the formula or to the general rinsing effect of any mouthwash. participants will be asked to use the investigated mouthwash or the comparative mouthwash twice a day for 21 days.

severity of gingival inflammation is evaluated using the loë \& silness scale, which includes 4 scores (0=no inflammation, 3=significant inflammation, redness, accentuated hypertrophy with spontaneous hemorrhagic tendency and ulceration) by the dentist, on day 0 and on day 7. presence of dental plaque is evaluated using the loë \& silness scale, which includes 4 scores (0=no dental plaque, 3=abundant plaque along the gingival margin; the spaces between the teeth are filled with plaque) by the dentist, on day 0 and on day 7. changes in the gingival microbiota is evaluated through the analysis of bacteria on d0 and d7 by swab sampling on the occlusal and buccal surfaces at the gum line. tolerance (adverse effects) will also be studied by recording any adverse effect.

Eligibility criteria:
inclusion criteria: * person (man, woman) aged 18 or over, * person with a gingival index ≥ 2 (according to loë \& silness) on at least 10% of teeth (i.e. 3 teeth) at the inclusion visit * person capable of following the instructions for using the product, * person agreeing to come for a dental consultation 7 days (+/- 1 day) after the inclusion visit, * volunteer informed and having signed their informed consent form, * volunteer person affiliated to a social security scheme (art l1121-11 of the csp). exclusion criteria: * person who has regularly used mouthwash in the last month, * person suffering from periodontitis * person having a scaling treatment planned in the session, or having had a scaling treatment in the 6 months preceding the inclusion visit, * person having had antibiotic or antifungal treatment in the 3 months preceding the visit, * person taking anti-coagulant or anti-aggregant or immunosuppressive or anti-cancer treatment (chemotherapy or radiotherapy of the head and neck) * person at risk of infective endocarditis, * person with a known sensitivity or allergy to one of the components of mouthwashes, including components derived from essential oils (eucalyptol, thymol, menthol, limonene). * volunteer participating in intervention research. * vulnerable people referred to in articles l. 1121-5 to 8 and l. 1122-1-2 of the public health code (institutionalized volunteers, deprived of their liberty or placed under legal protection (guardianship or curatorship).
secondary hiv prevention and adherence among hiv-infected drug users

Conditions: Risk Behavior; Medication Adherence; HIV

Summary: this study will test whether 3h+ (holistic health for hiv) is comparable to the original hhrp+ (holistic health recovery program) in reducing hiv risk behaviors and improving art (antiretroviral therapy) adherence in a randomized controlled comparative effectiveness trial among 256 hiv+ persons in drug treatment who report unsafe injection drug use practices or sexual risk behavior.

hiv-infected drug users (dus) remain a target population as they represent a significant vector for the transmission of new hiv infections (avants et al., 2004; margolin et al., 2003), which occur through preventable drug- and sex-related hiv risk behaviors. though numerous evidence-based hiv risk reduction interventions are now widely available as complete intervention packages, few evidence-based interventions have been designed for implementation within common drug treatment community-based organizations (cbos), such as methadone maintenance programs (mmps), where many high-risk hiv-infected drug users seek treatment. moreover, the few evidence-based interventions that are applicable to drug treatment cbos are not designed to be "community-friendly" and, hence, are unlikely to be implemented as intended or durable within these critical settings. the investigators have developed a significantly shortened version of the comprehensive evidence-based holistic health recovery program (hhrp; avants et al., 2004; margolin et al., 2003). this shortened version, holistic health for hiv (3h+), has demonstrated feasibility and acceptability as well as preliminary evidence of effectiveness in an uncontrolled study within a resource-limited drug treatment cbo. therefore, this randomized controlled comparative effectiveness trial (rct) will test the efficacy and cost-effectiveness of 3h+ versus the original gold standard evidence-based intervention(ebi), holistic health recovery program for hiv+s (hhrp+), targeting hiv+ drug users (dus).

Eligibility criteria:
inclusion criteria: * hiv positive * opioid dependent and enrolled in methadone maintenance treatment * report drug- or sex-related hiv risk behavior in previous 6 months * able to read and understand the questionnaires, the audio computer assisted self interview (acasi), and consent form * available for the full duration of the study with no anticipated circumstances impeding participation * not actively suicidal, homicidal, or psychotic as assessed by trained research staff under the supervision of the pi who is a licensed clinical psychologist in connecticut. exclusion criteria: -

Keywords: viral load hiv cd4 methadone maintenance substance use antiretroviral therapy (art)
effect of uterine manipulator on recurrence and mortality of endometrial cancer

Conditions: Endometrial Cancer

Summary: the investigators sought to retrospectively assess whether the use of a intrauterine device to manipulate the uterus does affect the long-term oncologic outcomes of patients operated by laparoscopy for endometrial cancer

the investigators retrospectively collected data regarding patients who received operation by laparoscopy for presumed clinical stage i endometrial cancer. the subjects were then stratified according to the use or not of the uterine manipulator. the investigators also considered the actual type of manipulator used. then disease-free, disease-specific and overall survival were evaluated, as well as all the possible factors associated with prognosis. data were retrieved from specifically designed research quality internal surgical databases, prospectively updated by trained residents on a regular basis, in order to capture all the possible surgical and follow-up data.

Eligibility criteria:
inclusion criteria: * clinical stage i endometrial cancer * laparoscopic operation exclusion criteria: * post-operative oncologic follow-up \< 12 months * extra-uterine evidence of disease

Keywords: endometrial cancer survival uterine manipulator